Could diabetes drugs be the key to halting heart disease?

NCT ID NCT07254572

Recruiting now Disease control Sponsor: National Institute of Cardiology, Warsaw, Poland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two newer diabetes drugs, semaglutide and dapagliflozin, against the standard drug metformin in 300 people with pre-diabetes and coronary artery disease. The goal is to see which drug best slows or reverses the buildup of plaque in heart arteries over 24 months. Participants will take the medication long-term to manage their condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE PREDIABETES

Contacts and locations

Locations

National Institute of Cardiology, Department of Coronary Artery and Structural Heart Diseases
RECRUITING

Warsaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.